XML 28 R7.htm IDEA: XBRL DOCUMENT
v3.25.1

REVENUE | 3 Months Ended
--- | ---
Mar. 31, 2025
Revenue from Contract with Customer [Abstract] |
REVENUE | REVENUE The following table summarizes the disaggregation of revenue by nature:
| Three Months Ended March 31, |  |
Dollars in millions | 2025 |  | 2024 |  |  |  |
Net product sales | $ | 10,886 |  |  | $ | 11,559 |  |  |  |  |
Alliance revenues | 88 |  |  | 134 |  |  |  |  |
Other revenues | 227 |  |  | 172 |  |  |  |  |
Total Revenues | $ | 11,201 |  |  | $ | 11,865 |  |  |  |  |
The following table summarizes GTN adjustments:
| Three Months Ended March 31, |  |
Dollars in millions | 2025 |  | 2024 |  |  |  |
Gross product sales | $ | 19,874 |  |  | $ | 19,295 |  |  |  |  |
GTN adjustments(a) |  |  |  |  |  |  |
Charge-backs and cash discounts | (2,958) |  |  | (2,556) |  |  |  |  |
Medicaid and Medicare rebates | (3,840) |  |  | (3,084) |  |  |  |  |
Other rebates, returns, discounts and adjustments | (2,190) |  |  | (2,096) |  |  |  |  |
Total GTN adjustments(b) | (8,988) |  |  | (7,736) |  |  |  |  |
Net product sales | $ | 10,886 |  |  | $ | 11,559 |  |  |  |  |
(a) Includes reductions to GTN adjustments for product sales made in prior periods resulting from changes in estimates of $289 million and $80 million for the three months ended March 31, 2025 and 2024, respectively. (b) Includes U.S. GTN adjustments of $8.2 billion and $6.9 billion for the three months ended March 31, 2025 and 2024, respectively. The following table summarizes the disaggregation of revenue by product and region:
| Three Months Ended March 31, |  |
Dollars in millions | 2025 |  | 2024 |  |  |  |
Growth Portfolio |  |  |  |  |  |  |
Opdivo | $ | 2,265 |  |  | $ | 2,078 |  |  |  |  |
Opdivo Qvantig | 9 |  |  | — |  |  |  |  |
Orencia | 770 |  |  | 798 |  |  |  |  |
Yervoy | 624 |  |  | 583 |  |  |  |  |
Reblozyl | 478 |  |  | 354 |  |  |  |  |
Opdualag | 252 |  |  | 206 |  |  |  |  |
Breyanzi | 263 |  |  | 107 |  |  |  |  |
Camzyos | 159 |  |  | 84 |  |  |  |  |
Zeposia | 107 |  |  | 110 |  |  |  |  |
Abecma | 103 |  |  | 82 |  |  |  |  |
Sotyktu | 55 |  |  | 44 |  |  |  |  |
Krazati | 48 |  |  | 21 |  |  |  |  |
Cobenfy | 27 |  |  | — |  |  |  |  |
Other Growth products(a) | 403 |  |  | 325 |  |  |  |  |
Total Growth Portfolio | 5,563 |  |  | 4,792 |  |  |  |  |
Legacy Portfolio |  |  |  |  |  |  |
Eliquis | 3,565 |  |  | 3,720 |  |  |  |  |
Revlimid | 936 |  |  | 1,669 |  |  |  |  |
Pomalyst/Imnovid | 658 |  |  | 865 |  |  |  |  |
Sprycel | 175 |  |  | 374 |  |  |  |  |
Abraxane | 105 |  |  | 217 |  |  |  |  |
Other Legacy products(b) | 199 |  |  | 228 |  |  |  |  |
Total Legacy Portfolio | 5,638 |  |  | 7,073 |  |  |  |  |
Total Revenues | $ | 11,201 |  |  | $ | 11,865 |  |  |  |  |
United States | $ | 7,873 |  |  | $ | 8,476 |  |  |  |  |
International(c) | 3,110 |  |  | 3,190 |  |  |  |  |
Other(d) | 218 |  |  | 199 |  |  |  |  |
Total Revenues | $ | 11,201 |  |  | $ | 11,865 |  |  |  |  |
(a) Includes Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues. (b) Includes other mature brands. (c) Includes Puerto Rico. (d) Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations. Revenue recognized from performance obligations satisfied in prior periods was $444 million and $182 million for the three months ended March 31, 2025 and 2024, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration